openPR Logo
Press release

Cough Suppressant Drugs Market Development Industry 2019 Featuring with Top Players Perrigo, Vernalis, Tris Pharma ,Pfizer, Aytu BioScience, Acella Pharmaceuticals

05-22-2019 12:59 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Coherent Market Insights

Cough Suppressant Drugs

Cough Suppressant Drugs

In March 2018, Perrigo Company plc. received the FDA approval for the brand OTC equivalent of Mucinex DM Maximum Strength (Guaifenesin and Dextromethorphan Hydrobromide Extended-release Tablets, 1200 mg/60 mg). Mucinex DM Maximum Strength is indicated to control coughs and to break up mucus, making coughs more productive. Approval and launch of such new drugs in the market is expected to drive the cough suppressant drugs market growth over the forecast period.

High prevalence of cough is also expected to be a major factor for rising demand for cough suppressant drugs, which drives the market growth. For instance, according to the data published by the National Center for Biotechnology Information in 2014, cough is the most common reason for visits to primary care physicians globally, accounting for around 8% of all consultations. According to the same source, the annual prevalence of cough in the general population is reported as approximately 10–33% globally.

The global cough suppressant drugs market size was valued at US$ 1100.4 Mn in 2017 and is expected to witness a CAGR of 3.7% during the forecast period (2018 – 2026).

North America is expected to hold dominant position, owing to frequent approvals of new cough suppressant drugs by FDA

North America cough suppressant market is expected to show good growth over the forecast period, owing to frequent approvals to novel drugs by the FDA. For instance, in 2015, Vernalis plc and Tris Pharma Inc. received the U.S. Food and Drug Administration (FDA) approval for the New Drug Application (NDA) for Tuzistra XR (codeine polistirex and chlorpheniramine polistirex) extended-release oral suspension, CIII (DEA Schedule III). Tuzistra XR is a codeine-based extended-release oral suspension for cough-cold treatment.

Request A Sample Copy:
https://www.coherentmarketinsights.com/insight/request-sample/2427

Key players in the market are involved in strategic mergers and partnerships, in order to develop, manufacture, and sell novel cough suppressant drugs and to gain major market share.

For instance, in 2015, Tris Pharma, Inc. entered into a license, supply, and distribution agreement with Pfizer Consumer Healthcare (a part of Pfizer Inc.). According to the agreement, Pfizer Consumer Healthcare will commercialize Tris’ extended release dextromethorphan cough syrup under the Robitussin Brand. In exchange, Tris will provide the U.S. branded rights to its protected intellectual property for an extended release dextromethorphan formulation to Pfizer Consumer Healthcare and Tris will receive an upfront payment, milestone payments, and sales-based royalties. Various new players are entering lucrative cough suppressant drugs market by partnering with other manufacturers. For instance, in November 2018, Aytu BioScience, Inc., a specialty pharmaceutical company, entered into the cough suppressant drugs market with an exclusive license of FDA-approved Tuzistra XR from Tris Pharma Inc. Along with Tuzistra XR, Aytu BioScience, Inc. also has a licensed complementary antitussive product with pending FDA approval.

However, stringent regulations against the use of cough suppressant is expected to affect the global cough suppressant drugs market growth over the forecast period.

For instance, in February 2018, the Therapeutic Goods Administration reclassified codeine as prescription only medicine in Australia, which was previously available as over-the-counter medication. This reclassification was made, as regular use of medicines containing codeine may lead to its addiction. In January 2018, the U.S. Food and Drug Administration made safety labeling changes to limit the use of codeine or hydrocodone containing prescription opioid cough and cold medicines in children younger than 18 years old to protect kids from serious risks of opioid ingredients containing cough treatment drugs. After the safety labeling changes, these products will no longer be indicated for treatment of cough in pediatric population and will be labeled for use only in adults aged 18 years and older.

Key players operating in the global cough suppressant drugs market include Perrigo Company plc, Vernalis plc, Tris Pharma Inc., Pfizer Inc., Aytu BioScience, Inc., Acella Pharmaceuticals LLC, Mayne Pharma Inc., Taro Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Aurobindo Pharma Ltd, and GlaxoSmithKline plc.

Download the PDF brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/2427

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Cough Suppressant Drugs Market Development Industry 2019 Featuring with Top Players Perrigo, Vernalis, Tris Pharma ,Pfizer, Aytu BioScience, Acella Pharmaceuticals here

News-ID: 1749113 • Views: 520

More Releases from Coherent Market Insights

Flash-based Array Market Insights Into the Competitive Scenario of the Most Grow …
𝗧𝗵𝗲 𝗴𝗹𝗼𝗯𝗮𝗹 𝗙𝗹𝗮𝘀𝗵-𝗯𝗮𝘀𝗲𝗱 𝗔𝗿𝗿𝗮𝘆 𝗠𝗮𝗿𝗸𝗲𝘁 𝗶𝘀 𝗲𝘅𝗽𝗲𝗰𝘁𝗲𝗱 𝘁𝗼 𝗲𝘅𝗵𝗶𝗯𝗶𝘁 𝗮 𝗖𝗔𝗚𝗥 𝗼𝗳 𝟭𝟴.𝟬% 𝗗𝘂𝗿𝗶𝗻𝗴 𝘁𝗵𝗲 𝗙𝗼𝗿𝗲𝗰𝗮𝘀𝘁𝗲𝗱 𝗽𝗲𝗿𝗶𝗼𝗱 (𝟮𝟬𝟭𝟵-𝟮𝟬𝟮𝟳) Summary of the Report - CMI's latest report, global "Flash-based Array Market" Research 2022, provides a qualitative analysis of the top emerging regions, including development trends, CAGR value, expected growth, constraints, and the supply-demand environment of top companies - Tintri, Inc., Hitachi Data Systems Corporation, IBM Corporation, Tegile Systems, Inc., Oracle Corporation, Kaminario
Flash-based Array Market Insights Into the Competitive Scenario of the Most Grow …
𝗧𝗵𝗲 𝗴𝗹𝗼𝗯𝗮𝗹 𝗙𝗹𝗮𝘀𝗵-𝗯𝗮𝘀𝗲𝗱 𝗔𝗿𝗿𝗮𝘆 𝗠𝗮𝗿𝗸𝗲𝘁 𝗶𝘀 𝗲𝘅𝗽𝗲𝗰𝘁𝗲𝗱 𝘁𝗼 𝗲𝘅𝗵𝗶𝗯𝗶𝘁 𝗮 𝗖𝗔𝗚𝗥 𝗼𝗳 𝟭𝟴.𝟬% 𝗗𝘂𝗿𝗶𝗻𝗴 𝘁𝗵𝗲 𝗙𝗼𝗿𝗲𝗰𝗮𝘀𝘁𝗲𝗱 𝗽𝗲𝗿𝗶𝗼𝗱 (𝟮𝟬𝟭𝟵-𝟮𝟬𝟮𝟳) Summary of the Report - CMI's latest report, global "Flash-based Array Market" Research 2022, provides a qualitative analysis of the top emerging regions, including development trends, CAGR value, expected growth, constraints, and the supply-demand environment of top companies - Tintri, Inc., Hitachi Data Systems Corporation, IBM Corporation, Tegile Systems, Inc., Oracle Corporation, Kaminario
Consumer Network Attached Storage (NAS) Market 2022 Global Competition by Opport …
𝗧𝗵𝗲 𝗴𝗹𝗼𝗯𝗮𝗹 𝗖𝗼𝗻𝘀𝘂𝗺𝗲𝗿 𝗡𝗲𝘁𝘄𝗼𝗿𝗸 𝗔𝘁𝘁𝗮𝗰𝗵𝗲𝗱 𝗦𝘁𝗼𝗿𝗮𝗴𝗲 (𝗡𝗔𝗦) 𝗠𝗮𝗿𝗸𝗲𝘁 𝗶𝘀 𝗲𝘅𝗽𝗲𝗰𝘁𝗲𝗱 𝘁𝗼 𝗲𝘅𝗵𝗶𝗯𝗶𝘁 𝗮 𝗖𝗔𝗚𝗥 𝗼𝗳 𝟵.𝟱% 𝗗𝘂𝗿𝗶𝗻𝗴 𝘁𝗵𝗲 𝗙𝗼𝗿𝗲𝗰𝗮𝘀𝘁 𝗽𝗲𝗿𝗶𝗼𝗱 (𝟮𝟬𝟭𝟵-𝟮𝟬𝟮𝟳) Summary of the Report - CMI's latest report, global "Consumer Network Attached Storage (NAS) Market" Research 2022, provides a qualitative analysis of the top emerging regions, including development trends, CAGR value, expected growth, constraints, and the supply-demand environment of top companies - D-Link Corporation, Seagate Technology Public Limited Company, Synology
Automated Fare Collection System Market Investment Activity From Established Com …
Global Automated Fare Collection System Market is expected to exhibit a CAGR of 11.1% during the forecast period (2019-2027), as highlighted in a report published by Coherent Market Insights Summary of the Report - CMI's latest report, global "Automated Fare Collection System Market" Research 2022, provides a qualitative analysis of the top emerging regions, including development trends, CAGR value, expected growth, constraints, and the supply-demand environment of top companies - Cubic

All 5 Releases


More Releases for Pharma

Global Deferasirox Market 2018 - Novartis, Cipla, Sun Pharma, Natco Pharma
Apex Market Reports, recently published a detailed market research study focused on the “Deferasirox Market” across the global, regional and country level. The report provides 360° analysis of “Deferasirox Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Deferasirox on the basis of
Big Pharma Outlook 2026
Boston, MA ReportsWorldwide has announced the addition of a new report title Big Pharma Outlook 2026 to its growing collection of premium market research reports. Pharmavitae Analytics casts its eye out to 2026 with challenging trends in healthcare management set to crystallize, Big Pharma will add $29.5bn in revenues out to 2026, generating $351bn in prescription pharmaceuticals at a low single-digit compound annual growth rate (CAGR) of 0.9%. Using in-house sales forecasts,
Erythrocyte Catalase Market 2017 - Sanofi, Palam Pharma, Bioxera, Zafax Pharma
Apex Research, recently published a detailed market research study focused on the "Erythrocyte Catalase Market" across the global, regional and country level. The report provides 360° analysis of "Erythrocyte Catalase Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Erythrocyte Catalase industry, and estimates the future trend of Erythrocyte Catalase market on
12th World Pharma Congress
Conference Series proudly announces 12th World Pharma Congress for 2017, during October 16-18, at Budapest, Hungary. Pharmaceutical innovation is an orderly, predictable process. Intensive research coverage is resulting in an abundant knowledge of the mechanisms driving drug discovery and development. Pharmaceutical Formulation Market size was USD $147billion in 2015 and is anticipated to reach around USD 175.1 billion by 2018. In USA, the total number of new drugs approved between
12th World Pharma Congress
Conference Series has taken an initiation to conduct International Pharma Congress worldwide. From several years Conference Series has been conducting Pharma Congress conferences in major continents like Europe, America and Asia Pacific. Previous conferences were held in city like USA, with success. Conference Series proudly announces 12th World Pharma Congress for 2017, during October 16-18, at Budapest, Hungary. Pharmaceutical innovation is an orderly, predictable process. Intensive research coverage is resulting
4th African Pharma Congress
In the light of this theme, the conference series aims to provide a forum for international researchers from various areas of pharmaceutical sciences like chemical processing, industrial practice, analytical methods and pharmacological actions by providing a platform for critical analysis of new agenda, and to share latest cutting-edge research findings and results about all aspects of Pharmacy We are honoured to invite pharmacists, researchers, professors, scientific communities, delegates, students, business